tucatinib Jun 2, 2021 FDA's Project Orbis Facilitating Earlier Access to Precision Oncology Drugs Outside US Premium Feb 22, 2021 Seagen's Tukysa Combination Garners UK Approval for Advanced HER2-Positive Breast Cancer Dec 11, 2020 EMA Committee Recommends Approval for Seagen's Tukysa in Advanced HER2-Positive Breast Cancer Sep 14, 2020 Merck Invests $1B, Pays $725M Upfront for Two Seattle Genetics Precision Oncology Drugs Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
